METiS Therapeutics Inc.

Founded in 2017 and based in Massachusetts, US, METiS Therapeutics Inc. is a discovery technology and therapeutics company that develops therapeutics technology to build a proprietary predictive artificial intelligence platform to redefine drug discovery. Chris Lai is the co-founder and CEO of the firm. In December 2021, METiS Therapeutics Inc.

raised USD 86 million in Series A funding co-led by China Life Capital and PICC PE including 5Y Capital, CMB International Capital Management, Frees Fund, Lightspeed Venture Partners, and Sequoia Capital. The company offers a METiS platform (AiTEM) that combines state-of-the-art AI data-driven algorithms, mechanism-driven quantum mechanics, and molecular dynamics simulations to calculate active pharmaceutical ingredient (API) properties, elucidate API-target and API-excipient interactions, and predict chemical, physical, and pharmacokinetic properties of small molecule and nucleic acid therapeutics in specific microenvironments. This enables efficient lead optimization, candidate selection, and formulation design. METiS also develops and in-licenses novel assets with a high therapeutic potential that could benefit from its data-driven platform.

The organization plans to use the December 2021 financing to advance its pipeline of novel assets with high therapeutic potential and the continued development of its AI-driven drug discovery and delivery platform.